Sentences with phrase «immunotherapy program»
About Blog The Issels Treatment is an immunotherapy program with an extenvsive 50 - year history in the treatment of advanced cancer.
https://blog.feedspot.com/
Dr. Abhijit has 23 years» experience in pharmaceutical research, clinical trials, targeted delivery system development, and most recently was Administrative Program Coordinator of the Cancer Immunotherapy Program at Huntsman Cancer Institute at University of Utah.
Mackall leads the Parker Institute for Cancer Immunotherapy at Stanford, which supports the Stanford University Cancer Immunotherapy Program.
Dr. Lawrence Fong is the co-leader of the Cancer Immunotherapy Program and the Efim Guzik Distinguished Professor in Cancer Biology at the University of California, San Francisco (UCSF) Comprehensive Cancer Center.
«These are very promising findings and, as the first study to demonstrate protection from Zika in the pregnancy setting, are an important development in our efforts to combat Zika virus,» said Michael Diamond, M.D., Ph.D., Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology, and Associate Director, Center for Human Immunology and Immunotherapy Program at Washington University School of Medicine, and a lead author on the Cell paper.
Dr. Pamela Ohashi, Director, Tumour Immunotherapy Program at the Princess Margaret Cancer Centre, University Health Network.
Read more about the Tumour Immunotherapy Program at http://www.pm-tumorimmunotherapyprogram.ca/
«It's a completely different way of treating cancer,» says pediatric oncologist Stephan Grupp, who directs the Cancer Immunotherapy Program at the Children's Hospital of Philadelphia.
«It appears that pregnant women infected with Zika can pass the virus to babies in utero and that newborns also may be susceptible to infection,» said Diamond, also an associate director of the university's Center for Human Immunology and Immunotherapy Programs.
Our AST - VAC immunotherapy programs employ three common elements of dendritic cells, telomerase antigen, and the LAMP signal sequence to stimulate robust and specific immune responses to cancer cells (Figure 1).
Not exact matches
«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.
Their paper, which appears in Nature Communications, describes how an immune cell recruited to the tumor induces the programmed suicide, or apoptosis, of the killer T cells harnessed by many immunotherapies.
«Dendritic cells are essential for prompting the immune response against malignant cells and for driving the clinical success of cancer immunotherapy, but their function is often defective in cancer patients,» said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment & Metastasis Program at program leader of the Immunology, Microenvironment & Metastasis Program at Program at Wistar.
Soon afterward, Allison returned to MD Anderson, lured by the opportunity to launch the center's $ 30 million Moon Shots immunotherapy research program.
In his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortality.
«The microbiome appears to shape a patient's response to cancer immunotherapy, which opens potential pathways to use it to assess a patient's fitness for immunotherapy and to manipulate it to improve treatment,» said Wargo, who is also co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.
On 29 September, AAAS hosted a lively online discussion on Reddit's «Ask Me Anything» (AMA) forum on implicit bias in science — a discussion Smith joined, along with Shirley Malcom, AAAS» director of Education and Human Resources programs, Caleph B. Wilson, a biomedical scientist with Cellectis, a biopharmaceutical company, and Avery Posey, Jr., an instructor in the Center for Cellular Immunotherapies at the Perelman School of Medicine at the University of Pennsylvania.
«Checkpoint inhibitors are one of the most exciting recent advances for cancers, but the mechanism by which most patients become resistant to these therapies has been a mystery,» says Victor E. Velculescu, M.D., Ph.D., program leader in the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and professor of oncology.
«Our findings point to two potential impacts from additional research — analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,» said Wargo, senior researcher on the project and co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.
Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Research.
About the Anna - Maria Kellen Clinical Accelerator The Anna - Maria Kellen Clinical Accelerator, the clinical research program of the Cancer Research Institute, leverages CRI's partnerships with nonprofit organizations, pharmaceutical and biotech companies, and academic research and treatment centers worldwide, to provide scientists and clinicians with expertise in cancer immunotherapy access to resources they need to advance ambitious clinical and translational research ideas, while simulataneous solving for competitive and regulatory hurdles that would otherwise impede innovation.
Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.
In addition to Amgen's work to improve cancer patient treatment through science - based innovation, CRI will also recognize the company's commitment to the broader scientific and patient communities, both through its support of CRI's Cancer Immunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherImmunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherImmunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapyimmunotherapy research.
Dr. Levitsky: This is the first time that Roche has formally established a cancer immunology and immunotherapy research and development program within its structure.
The program supports basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic.
Members of CRI's Cancer Immunotherapy Consortium (CIC) and the Immunoguiding Program (CIP) of the Germany - based Association for Cancer Immunotherapy (CIMT) announce the completion of the Minimal Information About T cell Assays (MIATA) Project to establish baseline requirements for reporting the results of T cell immune monitoring in clinical trials.
The Center for Cancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurrence.
«The unique program has access to a broad portfolio of drugs and targets with the hope of accelerating a cure to all cancers through immunotherapy research.»
A collaborative group including the CRI Cancer Immunotherapy Consortium (CIC), the Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP), and scientists at Stanford University launch the Minimal Information About T cell Assays (MIATA) Project, the first systematic effort to establish a framework for reporting immune monitoring data from T cell assays used in clinical trials, with the goal of fostering reliability of data to facilitate meaningful interpretation, comparison, and meta - analysis across clinical trials.
The rationale for using CT - 011, an immunotherapy antibody that blocks the programmed death (PD)-1 receptor, is to boost the function of the immune system by inhibiting PD - 1 whose function, in part, is to inhibit T - cell response.
Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.
Tags: Basic Sciences Division, Bezos, Bezos Family Immunotherapy Clinic, Colleen Delaney, Cord Blood Program, Harlan Robins, Human Biology, Nohla Therapeutics, Public Health Sciences, Taran Gujral, Transplant and Immunotherapy, Women in Science
The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.
Much of Rudensky's career unfolded at Sloan - Kettering Institute of the Memorial Sloan - Kettering Cancer Center in New York City, where he arrived in 2008 and is currently chair of the immunology program and director of the Ludwig Center for Cancer Immunotherapy.
Gosselies, Belgium — February 9, 2018 — iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs in two oral presentations at the upcoming Molecular Medicine Tri-Conference 2018, taking place from February 11 - 16, 2018 in San Francisco, CA.
The month - long campaign celebrates achievements in the field of immuno - oncology, with fundraising and awareness - building programs for cancer immunotherapy research.
He has been previously co-director of the Program of Immunology and Bio-Immuno therapy of Cancer and coordinator of the Cancer Immunotherapy and Gene Therapy Program.
At RPCI, he maintains an active research program focused on finding new and efficacious therapies for cancer based on immunotherapy and gene therapy, overseeing many scientists in his research lab.
Research in the Leukemia Program spans from direction of clinical trials to basic molecular studies of leukemia biology, immunotherapy and development of novel agents, and to mitigating the late effects of treatment in long - term survivors.
PD - 1, which stands for programmed cell death 1, is the second immune checkpoint pathway currently being targeted with immunotherapies.
A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.
Programmed death 1: a critical regulator of T - cell function and a strong target for immunotherapies for chronic viral infections.
A primary objective of the program is to start at the clinic, analyzing patient samples from clinical trials testing novel cancer immunotherapies and correlating these results with clinical outcomes.
Led by Christiana Davis, MD, (in collaboration with Dr. Peter Gabriel, Chief Oncology Informatics Officer and Abigail Doucette, MPH, Research Registry Program Manager), the Thoracic TCE has established project - based databases to track the demographics and response status of patients to immune - oncology treatments, as well as acquired resistance to standard therapies and novel targeted immunotherapies.
This may be best addressed by a tailored development paradigm,» says CIC Executive Committee member and a lead investigator in the ipilimumab clinical development program Jedd D. Wolchok, M.D., Ph.D., who is director of the Immunotherapy Clinical Trials Program at Memorial Sloan - Kettering Cancer Center in New Yorprogram Jedd D. Wolchok, M.D., Ph.D., who is director of the Immunotherapy Clinical Trials Program at Memorial Sloan - Kettering Cancer Center in New YorProgram at Memorial Sloan - Kettering Cancer Center in New York City.
Through the CIC program, the Cancer Research Institute conducts a number of important initiatives that seek among other things to build consensus across the field on key issues, to develop and implement new standards for carrying out and reporting immunological monitoring assays of therapeutic cancer vaccines, and to establish and promote the adoption of new criteria for evaluating the clinical impact of cancer immunotherapies.
Most recently, CRI has launched a new «venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical trials.
In an effort to accelerate the development, refinement, and approval of more cancer immunotherapies, the Cancer Research Institute has a developed a comprehensive strategy that draws upon several complementary resources and programs.
Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center
Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research Professor, Immunology, Microenvironment & Metastasis Program